ARCHIVES

The Antineoplaston Anomaly: How A Drug Was Used For Decades In Thousands Of Patients, With No Safety, Efficacy Data

This article is from The Cancer Letter archive.

Vol. 24 No. 36 | September 25, 1998

Download PDF Visit The Full Archive

Related Articles

Celgene Signs CRADA With NCI For Development Of CDC-501.

June 30, 2000

New Treatment Approaches Valuable For Cancer Pain, Quality Of Life

September 27, 2002

American Cancer Society Publishes CT Screening Guidelines for Lung Cancer

January 11, 2013

In Brief: Megastrol Acetate Still Under FDA Review; Mays Hired For NCI’s Technology Office

July 20, 1990

DCT Board Okays Concepts For New Trials In Imaging, Intraoperative RT

June 14, 1985

NCI CTEP Approved Trials For the Month of November

November 29, 2013